Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization

Journal of Vascular Surgery

Volumn 64, Issue 4, 2016, Pages 1009-1017.e3

  Sigvant, Birgitta ^a,b   Kragsterman, Björn ^c   Falkenberg, Mårten ^d   Hasvold, Pål ^e   Johansson, Saga ^e   Thuresson, Marcus ^f   Nordanstig, Joakim ^g  

^a CENTRAL HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^e ASTRAZENECA R AND D   (Sweden)

^f STATISTICON AB   (Sweden)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT;

AGED; ANTICOAGULANT THERAPY; ARTERY SURGERY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CRITICAL LIMB ISCHEMIA; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITAL READMISSION; HUMAN; INTERMITTENT CLAUDICATION; LEG REVASCULARIZATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACEUTICAL CARE; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; CARDIOVASCULAR DISEASES; CRITICAL ILLNESS; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; ISCHEMIA; KAPLAN MEIER METHOD; LOWER LIMB; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; REGISTER; RISK FACTOR; SECONDARY PREVENTION; SWEDEN; TIME FACTOR; TREATMENT OUTCOME; VASCULARIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CRITICAL ILLNESS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERMITTENT CLAUDICATION; ISCHEMIA; KAPLAN-MEIER ESTIMATE; LOWER EXTREMITY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SECONDARY PREVENTION; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84969157769     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2016.03.429     Document Type: Article

References (40)

1. 1 Fowkes, F.G., Rudan, D., Rudan, I., Aboyans, V., Denenberg, J.O., McDermott, M.M., et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 382 (2013), 1329–1340.
2. 2 Sigvant, B., Wiberg-Hedman, K., Bergqvist, D., Rolandsson, O., Andersson, B., Persson, E., et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg 45 (2007), 1185–1191.
3. 3 Achterberg, S., Cramer, M.J., Kappelle, L.J., de Borst, G.J., Visseren, F.L., van der Graaf, Y., et al. Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study. Eur J Cardiovasc Prev Rehabil 17 (2010), 424–430.
4. 4 Cooke, J.P., Chen, Z., A compendium on peripheral arterial disease. Circ Res 116 (2015), 1505–1508.
5. 5 Sigvant, B., Lundin, F., Wahlberg, E., The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. Eur J Vasc Endovasc Surg 51 (2016), 395–403.
6. 6 Pande, R.L., Perlstein, T.S., Beckman, J.A., Creager, M.A., Secondary prevention and mortality in peripheral artery disease: national health and Nutrition Examination study, 1999 to 2004. Circulation 124 (2011), 17–23.
7. 7 Rodriguez, F., Cannon, C.P., Steg, P.G., Kumbhani, D.J., Goto, S., Smith, S.C., et al. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry. Clin Cardiol 36 (2013), 721–727.
8. 8 Sigvant, B., Wiberg-Hedman, K., Bergqvist, D., Rolandsson, O., Wahlberg, E., Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease. Eur J Cardiovasc Prev Rehabil 16 (2009), 39–46.
9. 9 Norgren, L., Hiatt, W.R., Harris, K.A., Lammer, J., TASC II Working Group. TASC II section F on revascularization in PAD. J Endovasc Ther 14 (2007), 743–744.
10. 10 Rooke, T.W., Hirsch, A.T., Misra, S., Sidawy, A.N., Beckman, J.A., Findeiss, L.K., et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 58 (2011), 2020–2045.
11. 11 Hirsch, A.T., Haskal, Z.J., Hertzer, N.R., Bakal, C.W., Creager, M.A., Halperin, J.L., et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113 (2006), e463–e654.
12. 12 Tendera, M., Aboyans, V., Bartelink, M.L., Baumgartner, I., Clement, D., Collet, J.P., et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 32 (2011), 2851–2906.
13. 13 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002), 71–86.
14. 14 Nowygrod, R., Egorova, N., Greco, G., Anderson, P., Gelijns, A., Moskowitz, A., et al. Trends, complications, and mortality in peripheral vascular surgery. J Vasc Surg 43 (2006), 205–216.
15. 15 Swedvasc. The Swedish National Registry for Vascular Surgery. Available at: www.ucr.uu.se/swedvasc. Accessed September 15, 2014.
16. 16 Bjorck, M., Bergqvist, D., Eliasson, K., Jansson, I., Karlstrom, L., Kragsterman, B., et al. Twenty years with the Swedvasc registry. Eur J Vasc Endovasc Surg 35 (2008), 129–130.
17. 17 Troeng, T., Malmstedt, J., Bjorck, M., External validation of the Swedvasc registry: a first-time individual cross-matching with the unique personal identity number. Eur J Vasc Endovasc Surg 36 (2008), 705–712.
18. 18 Venermo, M., Lees, T., International Vascunet validation of the Swedvasc registry. Eur J Vasc Endovasc Surg 50 (2015), 802–808.
19. 19 Ludvigsson, J.F., Andersson, E., Ekbom, A., Feychting, M., Kim, J.L., Reuterwall, C., et al. External review and validation of the Swedish national inpatient register. BMC Public Health, 11, 2011, 450.
20. 20 Koster, M., Asplund, K., Johansson, A., Stegmayr, B., Refinement of Swedish administrative registers to monitor stroke events on the national level. Neuroepidemiology 40 (2013), 240–246.
21. 21 Wettermark, B., Hammar, N., Fored, C.M., Leimanis, A., Otterblad Olausson, P., Bergman, U., et al. The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16 (2007), 726–735.
22. 22 R Core Team. R: a language and environment for statistical computing. 2015, R Foundation for Statistical Computing, Vienna, Austria.
23. 23 Ferranti, K.M., Osler, T.M., Duffy, R.P., Stanley, A.C., Bertges, D.J., Association between gender and outcomes of lower extremity peripheral vascular interventions. J Vasc Surg 62 (2015), 990–997.
24. 24 Hultgren, R., Olofsson, P., Wahlberg, E., Sex-related differences in outcome after vascular interventions for lower limb ischemia. J Vasc Surg 35 (2002), 510–516.
25. 25 Berg, J., Bjorck, L., Lappas, G., O'Flaherty, M., Capewell, S., Rosengren, A., Continuing decrease in coronary heart disease mortality in Sweden. BMC Cardiovasc Disord, 14, 2014, 9.
26. 26 Feringa, H.H., van Waning, V.H., Bax, J.J., Elhendy, A., Boersma, E., Schouten, O., et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 47 (2006), 1182–1187.
27. 27 Annual report SWEDEHEART 2012. Scand Cardiovasc J 48:Suppl 63 (2014), 2–133.
28. 28 Berger, J.S., Krantz, M.J., Kittelson, J.M., Hiatt, W.R., Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 301 (2009), 1909–1919.
29. 29 Kudoh, T., Sakamoto, T., Miyamoto, S., Matsui, K., Kojima, S., Sugiyama, S., et al. Relation between platelet microaggregates and ankle brachial index in patients with peripheral arterial disease. Thromb Res 117 (2006), 263–269.
30. 30 Iwashima, Y., Horio, T., Suzuki, Y., Kihara, S., Rakugi, H., Kangawa, K., et al. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atherosclerosis 188 (2006), 384–390.
31. 31 Poredos, P., Jezovnik, M.K., Do the effects of secondary prevention of cardiovascular events in PAD patients differ from other atherosclerotic disease?. Int J Mol Sci 16 (2015), 14477–14489.
32. 32 Wise, J., Beta blockers are associated with increased risk of cardiovascular events after surgery. BMJ, 351, 2015, h5349.
33. 33 Hunyady, L., Catt, K.J., Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 20 (2006), 953–970.
34. 34 Asmar, R., Effect of antihypertensive agents on arterial stiffness as evaluated by pulse wave velocity: clinical implications. Am J Cardiovasc Drugs 1 (2001), 387–397.
35. 35 Ostergren, J., Sleight, P., Dagenais, G., Danisa, K., Bosch, J., Qilong, Y., et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 25 (2004), 17–24.
36. 36 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002), 7–22.
37. 37 Mohler, E.R. 3rd, Hiatt, W.R., Creager, M.A., Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108 (2003), 1481–1486.
38. 38 Thompson, P.D., Zimet, R., Forbes, W.P., Zhang, P., Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 90 (2002), 1314–1319.
39. 39 Regensteiner, J.G., Ware, J.E. Jr., McCarthy, W.J., Zhang, P., Forbes, W.P., Heckman, J., et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 50 (2002), 1939–1946.
40. 40 Stevens, J.W., Simpson, E., Harnan, S., Squires, H., Meng, Y., Thomas, S., et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg 99 (2012), 1630–1638.